KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Supernus Pharmaceuticals (SUPN) EBIAT (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed EBIAT for 15 consecutive years, with -$4.1 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIAT fell 126.78% to -$4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$38.6 million, a 152.19% decrease, with the full-year FY2025 number at -$38.6 million, down 152.19% from a year prior.
  • EBIAT was -$4.1 million for Q4 2025 at Supernus Pharmaceuticals, up from -$45.1 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $38.5 million in Q3 2024 to a low of -$45.1 million in Q3 2025.
  • A 5-year average of $7.5 million and a median of $6.8 million in 2021 define the central range for EBIAT.
  • Peak YoY movement for EBIAT: surged 2496.63% in 2024, then tumbled 9637.9% in 2025.
  • Supernus Pharmaceuticals' EBIAT stood at $2.4 million in 2021, then surged by 943.45% to $25.5 million in 2022, then crashed by 95.39% to $1.2 million in 2023, then skyrocketed by 1204.51% to $15.3 million in 2024, then crashed by 126.78% to -$4.1 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's EBIAT are -$4.1 million (Q4 2025), -$45.1 million (Q3 2025), and $22.5 million (Q2 2025).